I've previously posted on the merger between Merck and Schering Plough. As a shareholder in both companies, I voted for the merger. Apparently they are having a shake up in management at Merck, which seems to be unrelated to the pending merger.
The head of the vaccines unit announced her retirement as of November 1st, to pursue "personal and professional aspirations." Recently sales have been dropping off for their vaccine Gardasil and they have had manufacturing and supply issues for their vaccine for shingles. Some experts covering Merck believe this is the beginning of a significant change in management company wide, with some changes that will come as a surprise to shareholders. These changes are ultimately expected to enhance the value of the organization going forward.
To read more on this subject:
No comments:
Post a Comment